Other Events · Jun 8, 2026

Cullinan Therapeutics, Inc. announced initial Phase 1 OUTRACE clinical trial data for CLN-978 in patients with…

CGEMCullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. announced initial Phase 1 OUTRACE clinical trial data for CLN-978 in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The data showed significant B cell depletion and improvements in disease activity markers for both conditions, though a single case of Grade 3 cytokine release syndrome (CRS) was reported in the 45 <mu>g target dose cohort.